Compare BioNTech SE - ADR (BNTX) vs Kraft Heinz Co (KHC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Kraft Heinz Co — how do they compare? BioNTech SE - ADR trades at $92.94 (market cap $23.31B), while Kraft Heinz Co trades at $24.55 (market cap $29.23B). The key difference: Kraft Heinz Co is the larger of the two by market cap, and Kraft Heinz Co pays a 6.49% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | KHC | |
|---|---|---|
Market Cap | $23.31B | $29.23B |
Sector | Health | Consumer Staples |
52-Week High | $119.34 | $28.06 |
52-Week Low | $83.89 | $21.21 |
Enterprise Value | $6.60B | $45.55B |
Dividend Yield | — | 6.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $92.72, down 0.09% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 revenue of €106 million, missing expectations due to weak COVID-19 vaccine demand, and lowered its 2026 sales outlook. Despite negative profitability metrics (net income margin -63.64%, ROE -9.3%), the balance sheet remains strong with $16.78 billion in cash. Analyst consensus is strongly bullish with 87.5% buy ratings and a $121 price target.
The outlook for BNTX hinges on its oncology pipeline development amid declining COVID revenue. Investment opportunity exists in the discounted valuation relative to cash reserves and potential pipeline catalysts. Key risks include execution on pipeline transitions, competitive pressure, and ongoing vaccine demand volatility. The stock trades near cash value, implying the market assigns minimal value to its advanced clinical programs.
Kraft Heinz (KHC) trades at $24.48, down 1.81% on the day, with a bearish technical signal and mixed sentiment. The stock shows attractive valuation ratios like a P/E of 13.04 and P/B of 0.81, but fundamentals are pressured by a net loss of $5.85 billion in 2025 and negative profit margins. Recent quarters have beaten EPS estimates, and the company maintains a $0.40 quarterly dividend, though dividend sustainability concerns persist amid earnings erosion.
The outlook is cautious; while the stock appears undervalued and dividend yield is high, ongoing profit declines and sector headwinds pose risks. Analyst consensus is mixed with a $24 price target, and institutional selling adds pressure. Key catalysts include the success of CEO Cahillane's turnaround strategy, but execution risks and competitive threats remain significant hurdles for shareholder value recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →
